Billy Chang, MD, Pediatric Hematology & Oncology, Portland, OR


Pediatric Hematology & Oncology Portland, OR

Associate Professor of Pediatrics, Oregon Health & Sci University

Dr. Chang is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Chang's full profile

Already have an account?

  • Office

    3181 Sw Sam Jackson Park Rd
    Mailcode Cdrcp, Doernbecher Childrens Hospital
    Portland, OR 97239
    Phone(503) 494-1543
    Fax(503) 494-0714
  • Is this information wrong?

Education & Training

  • Oregon Health & Science University
    Oregon Health & Science UniversityFellowship, Pediatric Hematology/Oncology, 2003 - 2006
  • Oregon Health & Science University
    Oregon Health & Science UniversityResidency, Pediatrics, 2000 - 2003
  • Oregon Health & Science University School of Medicine
    Oregon Health & Science University School of MedicineClass of 2000
  • University of WashingtonB.S., Cell and Molecular Biology, 1991

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2003 - 2021
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • Portland Monthly’s Top Doctor of Pediatric Hematology and Oncology 2012
  • Hyundai Hope on Wheels 2012
  • Gene O’Brien Award Kiwanis Doernbecher Children’s Cancer Program, 2011
  • Join now to see all

Publications & Presentations


Journal Articles

  • Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes  
    Huan J, Hornick N, Goloviznina N, Kamimae-Lanning A, David L, Wilmarth P, Mori T, Chevillet J, Narla A, Roberts C Jr, Loriaux M, Chang BH, & Kurre P, Leukemia, 1/25/2015
  • Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML  
    Hornick N, Huan J, Doron B, Goloviznina N, Lapidus J, Chang BH, & Kurre P, Sci Rep, 1/1/2015
  • Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening  
    Tyner JT, Yang WF, Bankhead III A, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM,..., Cancer Res, 1/1/2013
  • Join now to see all


  • Targeting BCL-2 and BCR-ABL1 activity in Ph+ALL.
    Leonard J., Traer E, Hayes-Lattin B, Tyner JW, Druker BJ, & Chang BH, BMT Tandem Meeting, 1/11/2015
  • Synergy between targeted BCR-ABL1 and BCL-2 inhibitors is enhanced by the dual SRC/ABL inhibitors in Ph+ Acute lymphoblastic leukemia.
    Leonard J., Traer E., Tyner JW., Hayes-Lattin B., Loriaux M, Druker BJ, & Chang BH, Annual American Society of Clinical Oncology Meeting, Chicago, IL, 1/1/2015
  • Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therape...
    Burke MJ, Brown P, Gore L, Sposto R, Bhojwani D, Chang BH, Dubois SG, Gaynon PS, Glade-Bender J, Heym KM, Sulis ML, Pollard JA, Verma A, & Huynh V, 56th Annual American Society of Hematology Meeting, 1/4/2014
  • Join now to see all


  • CAR therapy. 
    Portland, OR - 1/1/2014
  • Dasatinib Sensitivity in Ph(-)ALL. 
  • -nibs, -mibs, and –mabs. Modern Cancer Warfare 
    Portland, OR - 1/1/2012
  • Join now to see all


  • Cloning and characterization of a novel family of inhibitory proteins of CaM-kinase II. Thesis Dissertation 
    Chang BH, Neuroscience Graduate Program